

Rubra Medicaments Limited

Statement of Standalone Unaudited Financial Results for the quarter and Half year ended September 30, 2020

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Year to date Figures for current period ended	Year to date Figures for previous period ended	Figures for the previous year ended
		30-Sep-2020	30-Jun-2020	30-Sep-2019	30-Sep-2020	30-Sep-2019	31-Mar-2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	8.75	0.00	14.00	8.75	23.26	98.76
II	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
III	Total Income (I + II)	8.75	-	14.00	8.75	23.26	98.76
IV	Expenses:						
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	0.00	0.00	10.00	0.00	10.00	14.68
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	0.60	0.60	2.41	1.20	8.96	13.06
	Finance Costs	0.01	0.00	0.02	0.01	0.11	0.12
	Depreciation & amortisation expense	0.08	0.00	0.04	0.08	0.09	0.17
	Other Expenses	7.45	0.00	0.75	7.45	2.17	69.16
	Total Expenses (IV)	8.14	0.60	13.22	8.74	21.33	97.19
V	Profit / (loss) before exceptional items and tax (III-IV)	0.61	-0.60	0.78	0.01	1.93	1.57
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	3.06
VII	Profit / (loss) before tax (V-VI)	0.61	-0.60	0.78	0.01	1.93	4.63
VIII	Tax Expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	1.45
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.03
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	0.61	-0.60	0.78	0.01	1.93	3.15
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	0.61	-0.60	0.78	0.01	1.93	3.15
XIV	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	0.61	-0.60	0.78	0.01	1.93	3.15
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.01	0.00	0.01	0.00	0.04	0.06
	(2) Diluted	0.01	0.00	0.01	0.00	0.04	0.06
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic						
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.06
XVIII	Earnings per equity share (for discontinued & continuing operation):						
	(1) Basic	0.01	0.00	0.01	0.00	0.04	0.06
	(2) Diluted	0.01	0.00	0.01	0.00	0.04	0.06
	NOTES:						
	1 The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.						
	2 The Segment - wise details are not applicable to the Company as the Company has no segments.						
	3. The result is provisional and unaudited and subject to change, regrouping and restatement.						

For Rubra Medicaments Limited

Place: Mumbai
Date: November 12, 2020

Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

RUBRA MEDICAMENTS LIMITED

(Rs. in Lakhs)

STATEMENT OF ASSETS AND LIABILITIES

	Particulars	Figures as at the end of	
		current reporting period	
		30-Sep-20	31-Mar-20
		Unaudited	Audited
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	1.44	1.52
	(b) Capital work-in-progress	-	-
	(c) Investment property	-	-
	(d) Goodwill	-	-
	(e) Other intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified) - Advances	-	-
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	-	-
	Total non-current assets	1.44	1.52
2	Current assets		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-0.30	29.00
	(iii) Cash and cash equivalents	23.11	0.05
	(iv) Bank balances other than (iii) above	0.83	0.03
	(v) Loans	47.01	41.51
	(vi) Others to be specified	-	-
	(c) Current tax assets (net)	-	-
	(d) Other current assets	3.20	3.20
	Total current assets	73.85	73.79
	Total assets	75.29	75.31
1	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	546.83	546.83
	(b) Other equity	-485.63	-485.63
	Total equity	61.20	61.20
	LIABILITIES		
2	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	-	-
	(d) Other non-current liabilities	-	-
	Total non-current liabilities	-	-
	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b))	-	-
	(b) Other current liabilities	-	-
	(c) Provisions, current	14.09	14.11
	(d) Current tax liabilities (Net)	-	-
	Total current liabilities	14.09	14.11
	Total liabilities	14.09	14.11
	Total Equity and Liabilities	75.29	75.31

For Rubra Medicaments Limited

Place: Mumbai

Date: November 12, 2020

Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

RUBRA MEDICAMENTS LIMITED

CASH FLOW STATEMENT FOR THE YEAR ENDED SEPTEMBER 30, 2020

	Particulars	September 30, 2020	March 31, 2020
		In Lakh	In Lakh
A	<u>Cash Flow From Operating Activities</u>		
	Net Profit before tax and Extraordinary Items	0.01	1.57
	Adjustment for :		
	Depreciation	0.08	0.17
	Operating Profit before working Capital Changes	0.09	1.74
	Adjustment for Capital Changes:		
	Increase/Decrease in Payables & Provisions	-0.02	8.25
	Increase/Decrease in Fixed Assets	-0.08	0.00
	Cash Generated From Operations	-0.01	10.00
	Income Tax / Deferred Tax Paid	0.00	1.45
	Extraordinary items	0.00	-3.06
	<u>Net cash from Operating Activities</u>	-0.01	11.61
B	<u>Net Cash From Investing Activities</u>		
C	<u>Cash Flow From Financing Activities</u>		
	Increase/Decrease in Trade Payables	0.00	-5.95
	Increase/Decrease in Cash Loans and advances	5.45	-19.99
	Increase/Decrease in Trade Receivables	-29.30	0.40
	<u>Net Cash From Financing Activities</u>	-23.85	-25.53
	Net Increase (Decrease) in cash & cash equivalents (A+B+C)	-23.86	-13.92
	Opening Balance of Cash & Cash Equivalents	0.08	14.00
	Closing Balance of Cash & Cash Equivalents	23.94	0.08

As per our Report of even date.

For and on behalf of Board of Directors
Rubra Medicaments Ltd

Mumbai
Date: November 12, 2020

Abha Kapoor
Director (Finance) & CFO
DIN: 02799429